Risk of Guillain-Barré syndrome following each dose of HPV vaccination: an 18-year nationwide self-controlled case series study

Background Although the safety of human papillomavirus (HPV) vaccines has been largely established, the risk of Guillain-Barré syndrome (GBS) remains uncertain. This study aimed to assess the dose-specific risk of GBS following HPV vaccination, considering the whole population targeted by the national vaccination program in France. Methods Using data from the French National Health Data System (SNDS), a self-controlled case series (SCCS) study was conducted, including all individuals aged 10–29 years hospitalized with a diagnosis of GBS from 2007 to 2024. The relative incidence (RI) of GBS during the 42-day risk periods following each HPV vaccine dose compared to control periods was estimated, adjusting for other vaccinations, concomitant respiratory and gastrointestinal infections, age, and seasonality. The number of excess cases attributable to HPV vaccination was derived. Results During the study period, 14.4 million (M) HPV vaccine doses (6.7 M first, 5.1 M second, 2.5 M third doses) were administered in a target population of 32.3 M individuals. Among 2604 GBS cases, 656 had received at least one dose of HPV vaccine, and 25 cases occurred within 42 days following HPV vaccination (9 after the first dose, 9 after the second, 7 after the third). No increase in GBS incidence was observed after the first vaccine dose (RI 1.29 [0.68–2.45]). In contrast, the incidence of GBS was increased after the second (RI 1.91 [1.01–3.60]) and third (RI 2.25 [1.06–4.79]) doses, a result consistent across sex, age subgroups and vaccine products. Accounting for the rarity of GBS, these relative increases resulted in 0.9 and 2.5 excess cases of GBS per million vaccinated individuals under a two-dose and three-dose schedule, respectively. Conclusion Although revealing a potentially heterogeneous risk profile across vaccine doses, this large study found no evidence of a substantial increase in the absolute risk of GBS following HPV vaccination, further confirming the safety of HPV vaccination.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-11-21
DOI
https://doi.org/10.1016/j.vaccine.2026.129372
Primary Topic
Peripheral Neuropathies and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Risk of Guillain-Barré syndrome following each dose of HPV vaccination: an 18-year nationwide self-controlled case series study

Jérôme Drouin, Lucas Dufour, Rosemary Dray-Spira, Stéphane Le Vu
Vaccine
Peripheral Neuropathies and Disorders
article

Risk of Guillain-Barré syndrome following each dose of HPV vaccination: an 18-year nationwide self-controlled case series study

Jérôme Drouin, Lucas Dufour, Rosemary Dray-Spira, Stéphane Le Vu
article en

Abstract

Background Although the safety of human papillomavirus (HPV) vaccines has been largely established, the risk of Guillain-Barré syndrome (GBS) remains uncertain. This study aimed to assess the dose-specific risk of GBS following HPV vaccination, considering the whole population targeted by the national vaccination program in France. Methods Using data from the French National Health Data System (SNDS), a self-controlled case series (SCCS) study was conducted, including all individuals aged 10–29 years hospitalized with a diagnosis of GBS from 2007 to 2024. The relative incidence (RI) of GBS during the 42-day risk periods following each HPV vaccine dose compared to control periods was estimated, adjusting for other vaccinations, concomitant respiratory and gastrointestinal infections, age, and seasonality. The number of excess cases attributable to HPV vaccination was derived. Results During the study period, 14.4 million (M) HPV vaccine doses (6.7 M first, 5.1 M second, 2.5 M third doses) were administered in a target population of 32.3 M individuals. Among 2604 GBS cases, 656 had received at least one dose of HPV vaccine, and 25 cases occurred within 42 days following HPV vaccination (9 after the first dose, 9 after the second, 7 after the third). No increase in GBS incidence was observed after the first vaccine dose (RI 1.29 [0.68–2.45]). In contrast, the incidence of GBS was increased after the second (RI 1.91 [1.01–3.60]) and third (RI 2.25 [1.06–4.79]) doses, a result consistent across sex, age subgroups and vaccine products. Accounting for the rarity of GBS, these relative increases resulted in 0.9 and 2.5 excess cases of GBS per million vaccinated individuals under a two-dose and three-dose schedule, respectively. Conclusion Although revealing a potentially heterogeneous risk profile across vaccine doses, this large study found no evidence of a substantial increase in the absolute risk of GBS following HPV vaccination, further confirming the safety of HPV vaccination.

VaccineVol. 96
Inserm (FR), Université Paris-Est Créteil (FR), Agence Nationale de Sécurité du Médicament et des Produits de Santé (FR), Epi-Phare (FR), Institut Mondor de Recherche Biomédicale (FR)
Peripheral Neuropathies and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon